Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study
详细信息 查看全文
- 作者：Mette S. van Ramshorsta ; Erik van Werkhovenb ; Aafke H. Honkoopc ; Vincent O. Dezentjé ; d ; Irma M. Ovinge ; Ingrid A. Mandjesb ; Inge Kempera ; Carolien H. Smorenburga ; Jacqueline M. Stoutharda ; Sabine C. Linna ; Gabe S. Sonkea ; g.sonke@nki.nl" class="auth_mail" title="E-mail the corresponding author ; on behalf of the Dutch Breast Cancer Research Group (BOOG)
- 关键词：Breast cancer ; Toxicity ; Human epidermal growth factor 2 ; Neoadjuvant treatment ; Trastuzumab ; Pertuzumab
- 刊名：The Breast
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：29
- 期：Complete
- 页码：153-159
- 全文大小：263 K
文摘
- •
Both FEC-T and PTC in combination with pertuzumab are well tolerated.
- •
Neutropenia was more common with pertuzumab in combination with FEC-T.
- •
Diarrhea was more common with pertuzumab in combination with PTC.